Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from Needham & Company LLC

Share on StockTwits

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a report released on Friday, AnalystRatings.com reports. They currently have a $18.00 price objective on the stock. Needham & Company LLC’s target price would suggest a potential upside of 328.57% from the stock’s previous close.

Separately, Zacks Investment Research raised Trevi Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, October 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Trevi Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $16.75.

TRVI stock traded up $0.30 during trading hours on Friday, hitting $4.20. 15,100 shares of the stock were exchanged, compared to its average volume of 17,847. The firm has a 50-day moving average price of $3.86. Trevi Therapeutics has a 12 month low of $2.65 and a 12 month high of $10.62.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Thursday, November 14th. The company reported ($0.41) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.07. Equities research analysts expect that Trevi Therapeutics will post -2.44 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Trevi Therapeutics during the second quarter valued at about $26,000. Morgan Stanley bought a new position in shares of Trevi Therapeutics during the second quarter worth about $42,000. Northern Trust Corp bought a new position in shares of Trevi Therapeutics during the second quarter worth about $124,000. Vanguard Group Inc. bought a new position in shares of Trevi Therapeutics during the second quarter worth about $886,000. Finally, Omega Fund Management LLC bought a new position in shares of Trevi Therapeutics during the second quarter worth about $9,476,000. 79.55% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Further Reading: The mechanics of the bid-ask spread in trading

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ignis Achieves Market Capitalization of $23.76 Million
Ignis Achieves Market Capitalization of $23.76 Million
United Community Banks  Upgraded at Zacks Investment Research
United Community Banks Upgraded at Zacks Investment Research
AIDUS TOKEN 1-Day Trading Volume Reaches $4,913.00
AIDUS TOKEN 1-Day Trading Volume Reaches $4,913.00
SAGE Therapeutics  Given New $100.00 Price Target at Oppenheimer
SAGE Therapeutics Given New $100.00 Price Target at Oppenheimer
GVC  Shares Cross Above 50 Day Moving Average of $851.59
GVC Shares Cross Above 50 Day Moving Average of $851.59
Energy Resources of Australia  Shares Pass Below 50-Day Moving Average of $0.20
Energy Resources of Australia Shares Pass Below 50-Day Moving Average of $0.20


© 2006-2019 Ticker Report